Finally, we demonstrated that the Her2/ErbB2 signaling is much more amplified in mutp53 (R172H) compared to p53null tumor cells in the MMTV-ErbB2 mouse breast cancer model, leading to a more aggressive disease (4). Here, ERBB2 is linked to breast carcinoma.